|
2025
|
P/S
|
administration of pharmaceutical reimbursement programs; providing information about patient reim... |
|
|
P/S
|
Pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparatio... |
|
2024
|
P/S
|
Pharmaceutical preparations for the treatment of cancer and oncological disorders, Alzheimer's di... |
|
|
P/S
|
Pharmaceutical research and development; Consulting services in the field of research and develop... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of Alzheimer's disease, Parkinson's disease, neurol... |
|
2023
|
Invention
|
Combination treatment of cancers with a bet inhibitor. Provided herein are methods of treating ca... |
|
|
Invention
|
Anti-cancer nuclear hormone receptor-targeting compounds.
The disclosure relates to anti-cancer ... |
|
|
Invention
|
Anti-cancer nuclear hormone receptor-targeting compounds. Provided herein are compounds comprisin... |
|
|
Invention
|
Anti-cancer nuclear hormone receptor-targeting compounds. The disclosure relates to anti-cancer c... |
|
|
Invention
|
Heterocyclic compounds as bet inhibitors.
Novel bromodomain and extraterminal domain (BET) inhib... |
|
2022
|
P/S
|
Pharmaceutical preparations for the treatment of cancer, oncological disorders, Alzheimer's disea... |
|
|
P/S
|
Pharmaceutical and biologic research and development; consulting services in the field of researc... |
|
|
Invention
|
Treating cancers with a cyclin-dependent kinase inhibitor.
The present disclosure relates to met... |
|
|
Invention
|
Treating cancers with a cyclin-dependent kinase inhibitor. The present disclosure relates to meth... |
|
|
Invention
|
Substituted pyrazolo[3,4-d]pyrimidines as wee1 inhibitors.
This invention provides for substitut... |
|
|
Invention
|
Heterocyclic compounds as kinase inhibitors. Heterocyclic compounds as CDK4 or CDK6 or other CDK ... |
|
|
Invention
|
Heterocyclic compounds and uses thereof.
Heterocyclic compounds as Wee1 inhibitors are provided.... |
|
|
Invention
|
Heterocyclic compounds as adenosine antagonists.
5,6-disubstituted 2-aminopyrazine compounds as ... |
|
|
Invention
|
1,8-naphthyridinone compounds and uses thereof.
1,8-naphthyridinone compounds as modulators of a... |
|
|
Invention
|
Crystalline forms of a cyclin-dependent kinase inhibitor.
Provided herein are crystalline forms ... |
|
|
Invention
|
Crystalline forms of a cyclin-dependent kinase inhibitor. Provided herein are crystalline forms o... |
|
2021
|
Invention
|
Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors.
Novel bromo... |
|
|
Invention
|
Heterocyclic compounds as kinase inhibitors.
Heterocyclic compounds as CDK4 or CDK6 or other CDK... |
|
|
Invention
|
Heterocyclic compounds as bet inhibitors. Novel bromodomain and extraterminal domain (BET) inhibi... |
|
|
Invention
|
Heterocyclic compounds as adenosine antagonists. Aminopyrazine compounds as modulators of an aden... |
|
2020
|
P/S
|
Pharmaceutical preparations for the treatment of cancer,
oncological disorders, Alzheimer's dise... |
|
|
P/S
|
Providing medical and scientific research information in the field of
pharmaceuticals |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer and
oncological disorders |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer and oncological disorders |
|
|
Invention
|
Heterocyclic compounds and uses thereof.
Heterocyclic compounds as Weel inhibitors are provided.... |
|
|
Invention
|
Compounds and uses thereof.
Compounds as modulators of an adenosine receptor are provided. The c... |
|
|
Invention
|
Heterocyclic compounds as adenosine antagonists.
Aminopyrazine compounds as modulators of an ade... |
